Medazol

Metronidazole, the active ingredient in Medazol, is a nitroimidazole antibiotic presented as a vaginal formulation for local use. It is prescribed to treat bacterial vaginosis, trichomoniasis and other vaginal infections caused by susceptible anaerobic microorganisms in adult women.

GNH USA supplies Medazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metazol belongs to the nitroimidazole class and is used to manage infections of the vaginal tract caused by anaerobic organisms. - Bacterial vaginosis: eliminates overgrowth of anaerobic bacteria, reducing discharge and odor. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving itching and irritation. - Anaerobic vaginal infections: treats infections caused by susceptible anaerobic bacteria, promoting symptom resolution.

Metazol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Vaginal irritation or burning - Itching or pruritus - Abnormal vaginal discharge - Mild nausea - Headache - Metallic taste

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity (jaundice, elevated liver enzymes) - Peripheral neuropathy (tingling, numbness) - Seizures - Severe colitis

Before using Medazol, consider the following safety measures. - Pregnancy: Category B; use only when clearly needed after risk‑benefit assessment. - Breastfeeding: Metronidazole is excreted in milk; consult a healthcare professional before use. - Alcohol: Avoid alcohol during treatment and for 48 hours after the last dose to prevent a disulfiram‑like reaction. - Liver or kidney impairment: Dose adjustment may be required; monitor function. - Allergies: Discontinue if signs of hypersensitivity appear. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Metazol can interact with several medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, nausea, vomiting. - Warfarin: increased anticoagulant effect, risk of bleeding. - Lithium: elevated lithium levels, potential toxicity. - Carbamazepine: reduced efficacy of metronidazole. - Phenytoin: decreased plasma concentration of metronidazole.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole levels. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Theophylline: increased theophylline concentrations. - Rifampicin: may lower metronidazole concentrations. - Bupropion: potential for increased side‑effects.